NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
Full-year revenue increased 10% to $727 million;Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition;Successfully resolved RaDaR ST patent litigation FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its fourth-quarter and full-year results for the period ended December 31, 2025.Fourth Quarter and Full Year 2025 Highlights Fourth quarter consolidated revenue increased 11% to $190 million; Full-year consolidated revenue increased 10% to $727 millionFourth quarter net loss decreased 36% to $10 million; Full-year net loss increased 37% to $108 millionFourth quarter adjusted EBITDA(1) increased 13% to positive $13 million; Full year adjusted EBITDA increased 9% to positive $43 million“We ended 2025 on a strong note, delivering double-digit revenue growth in the fourth quarter on the strength of our clinical volumes and ongoing m
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- 3 Reasons to Avoid NEO and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor TypesBusiness Wire
- NeoGenomics (NASDAQ:NEO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- NeoGenomics (NASDAQ:NEO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
NEO
Earnings
- 2/17/26 - Beat
NEO
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- NEO's page on the SEC website